These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7071776)

  • 1. [Pharmacometabolic capacity of the liver and the effect of pancreozymin in chronic hepatitis, chronic pancreatitis and diabetes mellitus].
    Geller LI; Griaznova MV; Bulgakova OS; Kozlova ZP
    Ter Arkh; 1982; 54(2):67-9. PubMed ID: 7071776
    [No Abstract]   [Full Text] [Related]  

  • 2. [The amylase and creatinine clearance coefficient in acute and chronic pancreatitis and diabetes mellitus].
    Zakrzewska I; Kuźma L
    Wiad Lek; 1985 Sep; 38(17):1199-203. PubMed ID: 3937339
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of inflammation and cholestasis on the metabolic function of the liver].
    Kogan AS; Nepomniashchikh VA
    Khirurgiia (Mosk); 1987 Feb; (2):79-81. PubMed ID: 3560745
    [No Abstract]   [Full Text] [Related]  

  • 4. Impairment of drug clearance in patients with diabetes mellitus & liver cirrhosis.
    Narang AP; Dutta DV; Khare AK
    Indian J Med Res; 1987 Mar; 85():321-5. PubMed ID: 3610277
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hepatic metabolism of antipyrine in patients with acute pancreatitis].
    Lukaszyk A
    Przegl Lek; 1987; 44(2):273-6. PubMed ID: 3615930
    [No Abstract]   [Full Text] [Related]  

  • 6. [Certain characteristics of the action of intestinal hormones in diseases of the digestive organs].
    Geller LI; Glinskaia TP; Kazimirchuk AP; Murzina NB; Ozherel'eva NIa
    Klin Med (Mosk); 1976 Oct; 54(10):63-8. PubMed ID: 1011728
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmaco-metabolic activity in chronic hepatopathies: influence of treatment with UDPG].
    Okolicsànyi L; Orlando R; Lirussi F; Naccarato R; Dal Brun G
    Clin Ter; 1980 May; 93(4):431-8. PubMed ID: 6998643
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evaluation of the vegetable oil taken up into the duodenum as a factor in pancreozymin liberation in healthy persons and in digestive organ diseases].
    Geller LI; Glinskaia TP; Kazimirchik AP; Ozherel'eva NIa
    Vopr Pitan; 1978; (1):13-5. PubMed ID: 629025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of beta-adrenolytic drugs on hepatic clearance of antipyrine].
    Adamska-Dyniewska H; Pruszczyński J; Wichan P
    Pol Arch Med Wewn; 1984 Feb; 71(2):71-7. PubMed ID: 6146126
    [No Abstract]   [Full Text] [Related]  

  • 10. Gross impairment of hepatic drug metabolism in a patient with chronic liver disease.
    Adjepon-Yamoah KK; Nimmo J; Prescott LF
    Br Med J; 1974 Nov; 4(5941):387-8. PubMed ID: 4425889
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hepatic elimination of indocyanine green and antipyrine in patients with chronic liver disease].
    Kuntz HD; Meessen D; May B
    Med Welt; 1982 Jun; 33(25):909-10. PubMed ID: 7109938
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drug metabolism in patients with liver disease (author's transl)].
    Richter E; Epping J; Fuchshofen-Röckel M; Heusler H; Zilly W
    Leber Magen Darm; 1980 Oct; 10(5):234-40. PubMed ID: 7464410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of pancreozymin on the absorptive capacity of the hepatocytes and liver circulation in chronic recurrent pancreatitis].
    Geller LI; Bulgakova OS; Petrenko VF
    Klin Med (Mosk); 1978 Jun; 56(6):72-6. PubMed ID: 672167
    [No Abstract]   [Full Text] [Related]  

  • 15. Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease.
    Krausz Y; Zylber-Katz E; Levy M
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):253-7. PubMed ID: 7450926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipyrine clearance and response to interferon therapy in chronic hepatitis.
    Fabbri A; Bianchi GP; Marchesini G
    Hepatology; 1997 Feb; 25(2):500-2. PubMed ID: 9021973
    [No Abstract]   [Full Text] [Related]  

  • 17. [Comparative studies with short-term prednisone treatment of diabetics and non-diabetics with chronic hepatitis and liver cirrhosis with special consideration of carbohydrate metabolism].
    Takác A; Bruns W; Langsch HG; Vetter K; Kublun G
    Dtsch Z Verdau Stoffwechselkr; 1965 Nov; 25(5):312-7. PubMed ID: 5888992
    [No Abstract]   [Full Text] [Related]  

  • 18. [Vitamin B 12 content of the liver].
    Kautzsch E
    Med Klin; 1972 Oct; 67(40):1275-7. PubMed ID: 4638146
    [No Abstract]   [Full Text] [Related]  

  • 19. Antidiabetic treatment for NASH?
    Maher J
    Hepatology; 2001 May; 33(5):1338-9. PubMed ID: 11343267
    [No Abstract]   [Full Text] [Related]  

  • 20. [Fatty acid composition of triglycerides in inflammatory liver diseases in diabetics with and without hyperlipoproteinemia].
    Singer P; Honigmann G; Schliack V
    Z Gesamte Inn Med; 1981 Aug; 36(15):513-9. PubMed ID: 7293284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.